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 ABSTRACT 
 The aim of this study was to evaluate vaccine efficacy 
of a commercial vaccine (Startvac, Hipra Spain) aimed 
at reducing intramammary infections (IMI) with Staph-
ylococcus aureus and coagulase-negative staphylococci 
under field conditions. During the 21-mo duration of the 
study, 1,156 lactations from 809 cows were enrolled in 2 
herds. During the first phase of the trial, all cows that 
were due to calve were vaccinated until approximately 
50% of cows in the milking herd were vaccinated (at ~6 
mo). At that point, when 50% vaccination coverage was 
reached, cows that were due to calve were randomly 
assigned to be vaccinated or left as negative controls. 
Cure rate, rate of new infection, prevalence, and dura-
tion of infections were analyzed. Vaccination resulted in 
a moderate reduction in incidence of new staphylococ-
cal IMI and a more pronounced reduction in duration 
of IMI associated with reduction of the basic reproduc-
tion ratio of Staph. aureus by approximately 45% and 
of coagulase-negative staphylococci by approximately 
35%. The utilization of vaccine in combination with 
other infection-control procedures, such as excellent 
milking procedures, treatment, segregation, and culling 
of known infected cattle, will result in an important 
reduction in incidence and duration of intramammary 
staphylococcal infections. 
 Key words:   Staphylococcus aureus ,  coagulase-negative 
staphylococci ,  intramammary infection ,  vaccine 
 INTRODUCTION 
 Mastitis is one of the most frequently occurring and 
costly diseases in dairy cows (Barkema et al., 2006; 
Halasa et al., 2007). Clinical mastitis is characterized 
by visible changes in milk, including the presence of 
clots, flakes, serum, or even blood inclusion. Subclini-
cal mastitis is characterized by increased SCC, reduced 
milk production, and, in many cases, a higher risk 
of early removal from the farm. Several preventative 
strategies have been applied to minimize the incidence 
of bovine mastitis, including optimization of milking 
procedures and milking hygiene, antibiotic therapies, 
vaccinations, segregation, and culling of persistently 
infected cows. However, mastitis remains an impor-
tant disease on many dairy farms and, due to the high 
costs of clinical mastitis, reduction in the severity of 
the symptoms of mastitis and obtaining a more rapid 
clearance of established infections is of great value to 
dairy farmers (Cha et al., 2011; Hertl et al., 2011). The 
severity of clinical symptoms of coliform mastitis has 
been shown to be reduced by immunization with com-
mercially available J-5 bacterin (Wilson et al., 2007). 
The efficacy of this vaccine for the prevention of mas-
titis caused by Escherichia coli has been investigated 
in experimental challenge studies (Wilson et al., 2007). 
These studies implied that immunization with J-5 bac-
terin reduced the severity of local and systemic signs of 
clinical mastitis following intramammary challenge. Ef-
ficacy of vaccination against Staphylococcus aureus and 
CNS is a very different concept than efficacy of vacci-
nation against E. coli (Torvaldsen and McIntyre, 2002). 
Whereas with E. coli the vaccine is mostly expected 
to reduce severity of infection, with Staph. aureus and 
CNS the vaccine is particularly valuable when vaccina-
tion results in a reduction of incidence and duration of 
infection, the key contributors to within herd infection 
dynamics (Schukken et al., 2011).  
 Vaccines against staphylococci have been studied and 
suggested as an important tool in the management of 
staphylococcal infections in dairy cows (Pereira et al., 
2011; Daum and Spellberg, 2012). Experimental chal-
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lenge studies with Staph. aureus have shown an effect of 
vaccination on the amount of bacterial shedding after 
challenge (Pérez et al., 2009); however, such experi-
mental studies were not able to demonstrate a reduc-
tion in infection transmission. Several study designs to 
estimate vaccine efficacy of contagious infections have 
been proposed (Haber et al., 1991; Halloran et al., 1991, 
1997, 1998). Randomization can take place at either 
the herd or at the individual animal level. To estimate 
the overall population vaccine efficacy using herd-level 
randomization, large numbers of vaccinated and control 
herds would be necessary. Within-herd randomization 
of cows to vaccination and control has obvious study 
size benefits, but is hampered by the potential herd 
immunity provided by vaccinates to the control animals 
in the same herd (Halloran et al., 1991). Comingling 
of vaccinated and control cows allows the calculation 
of direct vaccine efficacy, but this estimate of vaccine 
efficacy will be biased toward zero. This direct vaccine 
efficacy is an underestimation of the overall population 
vaccine efficacy due to the herd immunity of the vac-
cinated individuals that protect the unvaccinated con-
trols (Halloran et al., 1991). However, instead of basing 
vaccine efficacy on infection incidence, vaccine efficacy 
can be estimated based on infection transmission and 
infection duration parameters (Halloran et al., 1997). 
These infection dynamics parameters can be estimated 
from precisely documented infections in comingled 
populations, and the resulting vaccine efficacy turns 
out to be an unbiased estimate of overall population 
vaccine efficacy as long as the analysis is controlled for 
total exposure experience (Lu et al., 2009).
The number of vaccines against staphylococcal 
pathogens available on the market is small, and the 
efficacy of the results of these in peer-reviewed studies 
from commercial dairy farms is generally limited (Mid-
dleton et al., 2009). Recently, a combined staphylococ-
cal and J5 E. coli vaccine (Startvac, Hipra Spain), was 
introduced in the European market and, subsequently, 
in many other countries worldwide. The staphylococ-
cal component of the vaccine is based on a bacterin 
of Staph. aureus strains with particular high cell wall 
components, such as exopolysaccharides, that may be 
involved in the biofilm phenotype of the bacteria (Harro 
et al., 2010; Prenafeta et al., 2010).
To evaluate vaccine efficacy in the case of Staph. 
aureus and CNS infections, the infection status of quar-
ters of cows needs to be determined precisely over time 
(Halloran et al., 1997). Such precise data will allow the 
evaluation of vaccination on new IMI and IMI dura-
tion; at this point, few, if any, such studies have been 
reported in the literature. The objective of the current 
trial was to evaluate vaccine efficacy under field condi-
tions in 2 herds with a known infection prevalence of 
Staph. aureus and CNS.
MATERIALS AND METHODS
Herds
To evaluate vaccine efficacy we studied infection 
dynamics in 2 herds with a total of approximately 450 
dairy cows milking at any point in time. The herds 
had a known prevalence of Staph. aureus of at least 
5% of cows and a bulk milk SCC between 250,000 and 
400,000 cells/mL. Both herds used dry cow therapy on 
all quarters of all cows. Clinical mastitis cases were 
treated according to herd-specific protocols that were 
similar but not identical. Herd A had 2 dedicated milk-
ers that used a milking protocol with forestripping and 
wiping with single-use cloth towels. Herd B had one 
dedicated milker that used forestripping and wiping 
with single-use paper towels. Both herds used postmilk-
ing teat disinfection. Culling decisions were made by 
the farm owners based on fertility and lameness criteria 
in both herds.
The trial started in May 2011, with sampling, vacci-
nating, and collection data gathered on the farms until 
February 2013 for farm A, for a total of 21 mo, and 
October 2012 for farm B, for a total of 18 mo. Farm 
A maintained an average of 130 Holstein milking cows 
housed in freestall barns in deep-bedded cubicles with 
straw. Farm B maintained an average of 320 Holstein 
milking cows housed in freestall barns in deep-bedded 
cubicles with sawdust. On both farms, cows that were 
close to calving were moved to a loose-housing mater-
nity pen bedded with straw. Animals were housed for 
the first week of lactation in a large loose-housing pen 
with straw. After 1 wk of lactation, cows were moved 
to freestall facilities. All groups of cows in both dairies 
were fed a balanced TMR in feed alleys with headlocks 
that allowed restraint of cows for examination and ad-
ministration of treatments, medications, and vaccina-
tions. No segregation of cows based on IMI status or 
SCC level was done on either farm.
Milking Equipment Evaluation
On Farm A, cows were milked in a double-12 parallel 
parlor 2 times per day, whereas Farm B had a double-15 
herringbone parlor and cows were also milked 2 times 
per day. On the farms, milking equipment was evalu-
ated twice during the study period by technicians of the 
Regional Breeding Association using a complete ISO 
6690:2007-defined evaluation (ISO, 2007). Equipment 
evaluation took place at the beginning and at approxi-
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mately 1 yr into the study. No important concerns with 
milking equipment were identified on either farm.
Cow Data
Cow data on calving, parity, reproduction (AI dates, 
pregnancy), clinical disease (including retained placen-
ta, endometritis, metritis, lameness, clinical mastitis, 
and metabolic diseases such as ketosis, abortion, and 
displaced abomasum), and culling was collected for all 
cows in the herd. During the trial, Italian DHIA testing 
in both herds was done monthly for milk production, 
fat, protein, and SCC, but these data were not further 
analyzed for this report. All breedings on both farms 
were done using AI. Cow data were collected using a 
computerized herd record-keeping system (Dairy Comp 
305, Valley Agricultural Software, Tulare, CA).
Vaccination
Vaccination took place according to label directions 
in the dry period and early lactation. The first vaccina-
tion was at 45 d (±3 d) before the expected parturition 
date, the second vaccination at 35 d thereafter (±3 d), 
corresponding to 10 d before the expected parturition 
date, and the third vaccination was at 52 DIM (±3 d). 
No placebo or sham vaccination was used in this trial. 
Cows going through a second dry period during the 
study were kept in the same treatment group (vacci-
nated or control). At the start of the trial, all cows that 
were due to calve were vaccinated until approximately 
50% of cows in the milking herd were vaccinated (~6 
mo). At that point in time, when 50% vaccination 
coverage was reached, cows were randomly assigned to 
be vaccinated or left as controls. Trained farm person-
nel on farm A and the herd veterinarian on farm B 
performed all vaccinations. Assignment of vaccination 
was done using the European cow registration number, 
whereby even-numbered cows were vaccinated and odd-
numbered cows were kept as controls. Cows were identi-
fied in each farm using unique farm-specific ear tags. 
No logical relationship existed between the on-farm 
ear tag number and the official 13-digit European cow 
registration number. We thereby assume that this was 
essentially a randomized controlled and single-blinded 
trial, as the herd staff was not aware of the vaccination 
status of the animals.
Milk Sampling
Monthly quarter sampling of all lactating cows in 
herds was done during the trial period. In addition, 
quarters were sampled by the farm staff when a case 
of clinical mastitis occurred, when cows were dried off, 
upon calving, and at culling. Samplings related to dry 
off, calving, and culling were done within 24 h of the 
event. Sampling in cases of clinical mastitis was done 
upon detection, before treatment was applied. Before 
sampling, teat ends were carefully cleaned and disin-
fected with chlorhexidine. First streams of foremilk 
were discharged, and then approximately 10 mL of milk 
was collected aseptically from each teat into sterile vi-
als. Samples were stored at 4°C until bacteriological 
assays and SCC tests were initiated immediately after 
arrival back in the laboratory.
Bacteriological Analysis
Bacteriological cultures were performed according 
to standards of the National Mastitis Council (NMC, 
1999). Ten microliters of each milk sample were spread 
on blood agar plates (5% defibrinated sheep blood). 
Plates were incubated aerobically at 37°C and exam-
ined after 24 h.
Colonies were provisionally identified on the basis of 
morphology, hemolysis patterns, and Gram staining. 
Gram-positive organisms were differentiated in staphy-
lococci and streptococci by the catalase reaction. The 
coagulase tube test in rabbit plasma was used to differ-
entiate Staph. aureus and CNS species. Catalase- and 
coagulase-positive bacteria were reported as Staph. au-
reus, whereas catalase-positive and coagulase-negative 
species were reported as CNS. Catalase-negative organ-
isms had their identity confirmed by the API20Strep 
system (bioMerieux, Marcy l’Etoile, France), designed 
for Streptococcus spp. identification. Pathogens re-
ported as other Streptococcus spp. corresponded to 
species of streptococci that are less commonly reported 
in the literature or to pathogens that are not included 
in the API system identification panel. Gram-negative 
bacteria were identified by oxidase test, as well as by 
growth characteristics onto MacConkey agar (Oxoid 
Ltd., Basingstoke, UK) and Eosin Methylene Blue agar 
(Oxoid Ltd.; http://www.oxoid.com/UK/blue/prod_
detail/prod_detail.asp?pr=CM0069&org=66). Further 
identification was performed with the API20E and 
API20NE system (bioMerieux, Marcy l’Etoile, France). 
Gram-negative bacteria with very low prevalence that 
could not be identified by the methods described were 
reported as “other gram-negative.” The numbers of 
each colony type were recorded. Representative colonies 
were then subcultured on blood agar plates and incu-
bated again at 37°C for 24 h to obtain pure cultures. 
For plates with Staph. aureus and CNS growth, the 
number of colonies was recorded for each species iso-
lated, and colonies were reisolated and frozen for future 
characterization at −80°C in Nutrient Broth (Merck 
KGaA, Darmstadt, Germany) with 15% glycerol.
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Definition of Infection Status
Staphylococcus aureus was considered to cause an IMI 
if at least 1 colony (≥100 cfu/mL) was isolated. For 
CNS, IMI was defined by the isolation of at least 2 
colonies (≥200 cfu/mL) from a single sample or ≥100 
cfu/mL from a clinical sample. When multiple (at least 
2 out of 3) consecutive samples with ≥100 cfu/mL of 
CNS were identified, this was also considered an IMI. 
These definitions are based on the consensus opinion 
of mastitis research workers as published by Dohoo et 
al. (2011) and Andersen et al. (2010). A quarter was 
defined as uninfected and at risk for a new infection 
when 2 consecutive samples were culture-negative. An 
infection was considered cured if 2 consecutive monthly 
milk samples did not show the presence of the causative 
organism. Milk samples where 3 or more species were 
identified were considered contaminated. All culture 
results were kept from both farm staff and herd veteri-
narians until the very end of the study. When entering 
or leaving the trial, or reentering after calving, a single 
negative sample was considered sufficient to be defined 
as uninfected.
Statistical Analysis
Data were analyzed using the SAS version 9.2 system 
(SAS Institute Inc., Cary, NC). Descriptive analysis 
was done on all important outcome variables and co-
variates. Transformations were used where outcome 
variables were not normally distributed (e.g., SCC and 
cfu).
Logistic Regression Analysis—Risk Factors 
for New IMI and Cure of IMI. Linear regression 
models were used for analysis of crude prevalence and 
incidence of IMI. In these generalized linear models the 
only data were used after the 50/50 randomization in 
the herds had started. Every quarter-month at risk of 
either an incident or prevalent staphylococcal IMI con-
tributed a line of data to this analysis. The generalized 
linear model had the following format:
Logit (Y) = intercept + MIM + lactgroup  
+ herd + vaccination + complex error,
where Y is the outcome of interest (incidence or preva-
lence of Staph. aureus and CNS); MIM is months in 
milk; lactgroup is the lactation number of the cow, 
grouped into 1, 2, and 3+; herd is the herd code; and 
vaccination is either vaccinated or control. Complex 
error is a correlated error term where within-cow cor-
relation is combined with a random binomial error. 
Relevant interactions were evaluated in the model and 
included when statistically significant.
Duration of infection was estimated with the use of 
time-to-event analysis. Kaplan-Meier estimates of the 
survivor curves were used for graphical representation 
of the results. Cox regression was used for estimating 
the effect of vaccination on the duration of infection. 
For this analysis, only new infections were used that 
started after the 50/50 randomization in the herds had 
started.
Modeling Infection Dynamics. The rate of new 
infections per day at risk was calculated for vaccinated 
and control cows. The rates were calculated on a 
monthly basis (calendar months) for the duration of the 
trial. For evaluation of vaccine efficacy of Staph. aureus 
and CNS, the transmission rate (β), taking exposure 
into account, was calculated and compared between 
vaccinated and control cows. Exposure was based on 
the number of Staph. aureus- or CNS-shedding quarters 
at the same time in the herd. No distinction was made 
between infected quarters in the same cow and the sus-
ceptible quarters and infected quarters in other cows. 
The modeled relationship was defined as
New Staph. aureus or CNS infections(v/c) =  
β(v/c) × S(v/c) × (Iv + Ic) + covariates,
where v/c is vaccinated or control; S is the number 
of susceptible quarters; I is the number of infected 
quarters; and β is the transmission parameter. Vaccine 
efficacy for new infections may then be estimated as 
1− (βv/βc).
Similarly, cure of infection was modeled using 
Cure Staph. aureus or CNS infections(v/c) =  
α(v/c) × I(v/c) + covariates, 
where α is the cure rate of infections. Again, vaccine ef-
ficacy may then be estimated as 1 − (αv/αc). Estimates 
of α and β were obtained through linear models using 
Poisson regression (see also Lam et al., 1996; Barlow et 
al., 2013). The regression model for estimation of β was
 ln no. of new infections = b + covariates + offset,v/c v/c
*( )  
where the offset is given by ln {[Sv/c × (Iv + Ic)]/N}, 
where N is the total population size. The parameter β 
can then be calculated as exp(β*). For estimation of α, 
the Poisson regression equation was
 ln no. of cured infections = a + covariates + offset,v/c v/c
*( )  
where the offset is given by Ln (Iv/c). The parameter α 
was then calculated as exp(α*).
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The unit of analysis in both the regression analysis to 
estimate βV
*   and αV
*   was a calendar month. All data 
were used in this analysis, and a covariate that mea-
sured the month to or since the 50/50 vaccination point 
was included as a covariate in the model.
Population vaccine efficacy was estimated using the 
parameters α and β, where vaccine efficacy were re-
spectively defined as
 Vaccine efficacy for new infections = 1 ,vaccinated
control
−
β
β
 
whereas
 Vaccine efficacy for cure of infections = 1 control
vaccina
−
α
α ted
. 
Combining the information of parameters α and β 
into an overall infection reproduction ratio provides an 
unbiased summary parameter on vaccine efficacy. The 
basic reproduction ratio (R0) was defined as R0 = β/α, 
and the resulting vaccine efficacy is then calculated as
 1 10
0
− = −
( )
( )
R
R
,
,
/
/
.vaccinated
control
vaccinated
control
β α
β α
 
The variance of R0 may be calculated from the sum of 
the variance of the logarithm of the 2 components of 
R0: Var [ln (R0)] = Var (β
*) + Var (α*). This overall 
efficacy parameter is expected to provide the best sum-
mary of the overall effect of vaccination on infection 
dynamics in a vaccinated population (Halloran et al., 
2008).
Samples Size
The study was planned using a design of comingling 
vaccinates and controls with 1 control per vaccinate. 
As cow is the unit of vaccination, sample size calcula-
tions were performed at cow level. Prior data indicated 
that the new infection rate among controls is approxi-
mately 0.15 per lactation. This new infection risk of 
0.15 includes both Staph. aureus and CNS infections. 
If the true vaccine efficacy is at least 50%, then the 
new infection rate for vaccinated cows is 0.075 (Dohoo, 
2004). We needed to study at least 250 vaccinated cows 
and 250 control cows to be able to reject the null hy-
pothesis that the new infection rates for vaccinated and 
control cows were equal (efficacy = 0) with probability 
(= power) 0.8. The Type I error probability associated 
with this test of this null hypothesis is 0.05. Because 
of the within-cow dependency due to comingling (Hal-
loran et al., 1997), we estimated an increased sample 
size by approximately 25% resulting in at least 315 
cows per treatment arm, resulting in a study size of at 
least 630 cows in total.
RESULTS
Data Quality
Data checks and data entry occurred throughout 
study. Entry into the vaccination group was not as fast 
as expected on farm A, as pregnant heifers were initially 
not vaccinated. This was corrected in the database as 
soon as it was noted. For this reason, the farm reached 
the 50/50 point a few months later; thus, it was decided 
to keep the herd in the study for a longer period com-
pared with farm B. Data quality was checked through-
out the study and additional information on incomplete 
data points was collected where needed. Vaccination 
compliance was not always perfect during the trial; this 
is discussed in more detail herein.
Descriptive Statistics
During the entire study, a total of 1,156 lactations 
in 809 cows were identified in both herds; 658 cows 
(56.92%) were enrolled as controls, 343 cows (29.67%) 
were fully vaccinated, and 155 cows (13.34%) started 
the vaccination but were not fully vaccinated due to 
calving date estimation errors in pregnancy checking, 
early pregnancy loss, abortions, early calving, or end 
of the study. As vaccination was initially done on all 
cows calving into the lactating herd, the percentage of 
cows that were vaccinated increased rapidly in both 
herds. The percentage of vaccinated lactations in each 
herd throughout the trial is shown in Figure 1. In herd 
B, the 50/50 status was reached in mo 8 of the study, 
whereas in herd A this was at 11 mo into the study. 
Given that vaccinations start approximately 2 mo be-
fore anticipated calving, the change in randomization 
procedure started in herd B at 6 mo after the start of 
the study, whereas this was 9 mo after the start of the 
study in herd A.
Bacterial Culture Results
Throughout the study, 39,506 quarter milk samples 
were taken and used for bacterial culture. The results 
of bacterial culture of all these samples are shown in 
Table 1. The most commonly isolated pathogens in 
herd A were Staph. aureus (2,151; 15.6%) and CNS 
(937; 6.8%). In contrast, in herd B, CNS (1,139; 4.6%) 
were more frequently identified then Staph. aureus 
(929; 3.8%). Culture-negative status was observed in 
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9,503 samples (69%) for farm A and in 19,936 samples 
(80.5%) for farm B. Prevalence of Staph. aureus during 
the course of the study remained more or less stable in 
farm A, ranging from 19.6% at mo 1 to 14.8% at mo 22, 
but reduced dramatically in farm B from 10.5% at mo 
1 to 1.2% at mo 18.
In both farms, a fairly stable situation existed, 
without much change in prevalence of CNS IMI, rang-
ing from 5.0% at mo 1 to 9.2% at mo 22 for farm A 
and from 5.1% at mo 1 to 4.4% at mo 18 for farm 
B. When expressing prevalence by month in lactation, 
the data indicated a gradually increasing difference in 
Figure 1. Percentage of lactations that were either vaccinated or control. In herd A the 50/50 status was reached in mo 11 into the study, 
whereas in herd B this was at 8 mo.
Table 1. Bacterial results of all samples collected during the trial, monthly samples, dry off, calving, culling, 
and clinical mastitis cases 
Pathogen
Farm A Farm B
No. Percent No. Percent
Staphylococcus aureus 2,151 15.6 929 3.8
CNS 937 6.8 1,139 4.6
Streptococcus bovis 0 0.0 50 0.2
Streptococcus canis 1 0.0 4 0.0
Streptococcus dysgalactiae 19 0.1 176 0.7
Streptococcus mitis 14 0.1 36 0.1
Streptococcus uberis 132 1.0 217 0.9
Streptococcus spp. 89 0.6 117 0.5
Corynebacterium spp. 40 0.3 63 0.3
Enterococcus faecalis 38 0.3 55 0.2
Lactococcus lactis 11 0.1 70 0.3
Aerococcus viridans 58 0.4 88 0.4
Escherichia coli 81 0.6 191 0.8
Enterobacter spp. 19 0.1 17 0.1
Other gram-negative pathogen 52 0.4 36 0.1
Klebsiella spp. 6 0.0 116 0.5
Pasteurella spp. 2 0.0 8 0.0
Proteus spp. 63 0.5 65 0.3
Prototheca spp. 3 0.0 0 0.0
Serratia spp. 4 0.0 15 0.1
Trueperella pyogenes 0 0.0 2 0.0
Bacilli 5 0.0 26 0.1
Blind quarter 260 1.9 539 2.1
Missing or contaminated 671 2.0 1,452 3.5
Culture negative 9,503 69.0 19,936 80.5
Total 14,159 100 25,347 100
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prevalence between controls and vaccinates. This trend 
was present and statistically significant for both Staph. 
aureus and CNS IMI. The least squares means of the 
prevalence of infection for Staph. aureus and CNS is 
shown in Figures 2a and 2b.
Statistical Analysis
Logistic Regression and Cox Regression Analy-
sis—Risk Factors for New IMI and Cure of IMI. 
Risk of new IMI with Staph. aureus and CNS was ana-
lyzed by generalized linear regression analysis analyzing 
only new infections that occurred in cows calving after 
the 50/50 randomization had started. The final logistic 
regression models are shown in Table 2. For both Staph. 
aureus and CNS, new infections risk was not signifi-
cantly affected by vaccination (P > 0.05) when evalu-
ated as a main effect. For Staph. aureus, new infections 
increased with increasing DIM, increasing parity, and 
having a history of a previous Staph. aureus infection. 
Regression of new CNS infections showed a significant 
interaction between month in lactation and vaccination, 
Figure 2. Prevalence of Staphylococcus aureus (top) and CNS (bottom) IMI in all quarters during the course of the study in vaccinated and 
control (dash-dotted line) cows. Only cows that were eventually fully vaccinated were included in this analysis. As per vaccination protocol, 
vaccinated cows received 2 vaccinations at the start of lactation (2) and received the third and final dose (3) at approximately 53 DIM.
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where the risk of new infection was significantly lower 
(P < 0.05) in 2 of the 8 mo in lactation. Risk of new 
CNS IMI showed no pattern across month in milk or 
parity, with only parity 1 showing a lower new infection 
risk. A history of a previous CNS IMI turned out to 
be protective for the next new CNS IMI. Least squares 
means of the risk of new infections are shown for both 
Staph. aureus (Figure 3a) and CNS (Figure 3b).
Duration of infection was analyzed using Kaplan-
Meier estimates of the survivor curve. The survivor 
curves are shown in Figure 4a for Staph. aureus and in 
Figure 4b for CNS. Using Cox regression, the estima-
tion of hazard of curing an IMI by vaccination group 
resulted in a significantly increased hazard of ending 
the presence of infection in vaccinated versus control 
animals (P < 0.05). This was the case for both Staph. 
aureus and CNS (Table 3), but CNS IMI had a higher 
rate of cure, resulting in a shorter duration of infec-
tion for CNS compared with Staph. aureus (Table 3). 
Evidence for farm-specific patterns was also observed, 
with a higher risk of cure of Staph. aureus in farm B 
and a higher risk of cure of CNS in farm A.
Modeling Infection Dynamics. The monthly rate 
of new Staph. aureus infections was modeled in both 
herds using Poisson regression. First, it was evaluated 
whether evidence for contagious behavior of Staph. au-
reus existed by comparing a Poisson model with and 
without controlling for exposure to Staph. aureus (the 
offset term with and without). The difference between 
the model with and without controlling for Staph. au-
reus exposure was highly significant (P < 0.001), indi-
cating that a very clear contagious component to Staph. 
aureus infection exists in both herds.
Modeling the effect of vaccination on the rate of new 
infections, correcting for the total exposure experience, 
indicated that vaccination status was statistically sig-
nificant in an interaction with parity group. Vaccina-
tion was associated with a lower transmission param-
eter for new infections in lactation 1, a nonsignificant 
but numerically lower transmission parameter in parity 
2, and a significantly higher transmission parameter in 
lactations 3 and higher (3+). In herd B, transmission of 
Staph. aureus was lower compared with herd A. These 
regression results are shown in Table 4.
Modeling the rate of cure of infection indicated 
that vaccination significantly increased the cure rate 
of Staph. aureus infections, this finding was consistent 
across lactation groups (P < 0.0001), but different be-
tween the 2 herds. Herd B had a significantly better 
rate of cure compared with herd A (P < 0.0001). These 
results are shown in Table 5.
The monthly rate of new CNS IMI was also modeled 
using Poisson regression. The difference between the 
model with and without including exposure to CNS 
was highly significant, indicating that a very clear 
contagious component to CNS infection exists in both 
Table 2. Final logistic regression models of new Staphylococcus aureus and CNS IMI1  
Effect
Staph. aureus CNS
Estimate (SE) Pr > |t| Estimate (SE) Pr > |t|
Intercept  −3.48 (1.45) 0.02 −3.56 (0.52) <0.001
Staph. aureus or CNS history  0.60 (0.32) 0.06 −0.69 (0.29) 0.02
Month in lactation 1 −1.24 (0.38) 0.00 −0.13 (0.38) 0.73
 2 −0.90 (0.36) 0.01 0.91 (0.33) 0.01
 3 −0.68 (0.35) 0.05 0.28 (0.36) 0.44
 4 −0.29 (0.34) 0.40 0.16 (0.39) 0.67
 5 Baseline  Baseline  
 6 0.15 (0.36) 0.68 0.48 (0.37) 0.20
 7 0.19 (0.40) 0.64 −0.02 (0.04) 0.96
 8 0.32 (0.35) 0.36 −0.23 (0.39) 0.55
Lactation 1 −1.62 (0.27) <0.001 0.34 (0.16) 0.04
 2 −0.19 (0.21) 0.35 0.03 (0.17) 0.85
 3 Baseline  Baseline  
Vaccination Vaccinated 0.14 (0.20) 0.47 0.30 (0.51) 0.45
 Control Baseline  Baseline  
Vaccination × month in lactation 1 NS  −0.92 (0.60) 0.13
 2 NS  0.52 (0.59) 0.38
 3 NS  −1.01 (0.58) 0.08
 4 NS  −0.29 (0.64) 0.65
 5 NS  Baseline
 6 NS  −0.34 (0.64) 0.60
 7 NS  −0.32 (0.76) 0.68
 8 NS  −1.57 (0.68) 0.02
Herd B −2.84 (0.28) <0.0001 −0.89 (0.14) <0.0001
 A Baseline  Baseline  
1Only infections that occurred after the start of 50/50 randomization were used in this analysis. Herd was used as a random effect.
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herds (P < 0.001). No difference in new infection rate 
of CNS was shown between vaccinated and control 
cows (Table 2).
A significantly lower transmission parameter was 
observed in vaccinated cows (P < 0.001) in both herds 
(Table 4). Comparing the 2 herds, farm B again showed 
a lower transmission parameter in CNS infections 
compared with farm A (P < 0.001). These results are 
shown in Table 4.
Modeling the rate of cure of CNS IMI indicated that 
vaccination significantly increased the cure rate of 
CNS infections (P < 0.001); this finding was consistent 
across the 2 herds. Comparing the 2 herds, farm A had 
a significantly better cure and, therefore, a shorter du-
ration compared with farm B. These results are shown 
in Table 5.
Combining the transmission parameter and cure rate 
parameter into the overall basic reproduction ratio, R0, 
for Staph. aureus resulted in an R0 value of 0.89 (95% 
CI = 0.44–1.57) for vaccinated animals and a value of 
1.72 (95% CI = 1.06–3.17) for control cows. For CNS, 
the R0 value for vaccinated animals was 0.91 (95% CI 
= 0.78–1.14) and for control cows was 1.40 (95% CI = 
1.16–1.70).
Figure 3. Incidence of new Staphylococcus aureus (top) and new CNS (bottom) IMI by months in lactation in vaccinated and control 
(dash-dotted line) cows. Cows that eventually were fully vaccinated were included in this analysis. As per vaccination protocol, vaccinated cows 
received 2 vaccinations at the start of lactation (2) and received the third and final dose (3) at approximately 53 DIM.
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Vaccine Efficacy
For the transmission parameters, α and β, the vac-
cine efficacy is shown in the Table 6. The data indi-
cated that vaccine efficacy for transmission is relatively 
low; in Staph. aureus it is either 25% in lactation 1 
or nonsignificant but positive (16%) and even negative 
(−30%) in lactations 2 and 3+, respectively. For CNS 
the transmission vaccine efficacy was 21%, and this was 
consistent across lactations. Vaccine efficacy for cure is 
Figure 4. Survivor curves estimated from Cox time to event regression analysis. Shown here are time to cure of Staphylococcus aureus (top) 
and CNS (bottom) IMI.
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moderate, with a value of 41% for Staph. aureus and 
16% for CNS. For Staph. aureus, a significant difference 
in vaccine efficacy for cure was present between the 2 
farms; farm B showed a vaccine efficacy of cure of 52% 
and farm A was 30%. When parameter estimates for 
transmission and cure were combined into a vaccine ef-
ficacy for the basic reproduction ratio, then an efficacy 
of 33% was present for reduction in basic reproduction 
ratio in CNS across herds and across lactations. For 
Staph. aureus, vaccine efficacy was 56% for lactation 
1 animals, approximately 50% for lactation 2 animals, 
and dropped further to 24% in lactation 3+ animals. 
When estimated across all animals in both herds, ef-
ficacy of vaccination with regard to the basic reproduc-
tion ratio for Staph. aureus was 45%.
DISCUSSION
The key finding of the present study was a first es-
timate of the population efficacy of a staphylococcal 
vaccine affecting the transmission of infection. The ob-
served reduction in the basic reproduction ratio, R0, of 
approximately 35% in CNS and 45% in Staph. aureus, 
is encouraging, but at the same time highlights that 
vaccination is only an additional tool in the control 
of staphylococcal infections on dairy farms. For both 
CNS and Staph. aureus, vaccination resulted in moving 
the basic reproduction ratio from above to below the 
threshold of one. This basic reproduction ratio, with 
a value below 1, points toward a fade-out of infection 
in vaccinated groups. However, elimination of infection 
from a farm or a group of cows would only be possible 
when no new infection from sources other than shed-
ding herd mates occurs; in reality, infections from other 
sources are quite likely (Reksen et al., 2012; Barlow 
et al., 2013). In addition, the variability in this esti-
mate would allow individual farms to continue to have 
endemic staphylococcal IMI despite vaccination. Such 
variation in a basic reproduction ratio of staphylococ-
cal IMI has been observed before and was related to 
known infection risk factors (Lam et al., 1996, 1997; 
Reksen et al., 2012).
Table 3. Regression results of Cox time to event analyses1 
Parameter  Estimate SE Chi-square P-value
Hazard  
ratio
Staphylococcus aureus       
 Vaccination Vaccinated 0.24 0.12 3.88 0.05 1.27
 Control Baseline     
 Herd B −0.61 0.12 26.74 <0.0001 0.54
 A Baseline     
CNS       
 Vaccination Vaccinated 0.37 0.08 20.99 <0.0001 1.48
 Control Baseline     
 Herd B 0.25 0.08 9.13 <0.01 1.28
 A Baseline     
1Time to event here is time to cure for known newly infected quarters. Only infections occurring after the start of 50/50 randomization were 
used in this analysis. Results are shown for both Staph. aureus and CNS. 
Table 4. Modeling the transmission parameter (β*) using the rate of new Staphylococcus aureus and CNS 
infections in a Poisson regression model1 
Effect Category
Staph. aureus CNS
Estimate (SE) Pr > |t| Estimate (SE) Pr > |t|
β*  −1.22 (0.10) <0.0001 −0.25 (0.08) 0.00
Herd B −0.21 (0.10) 0.03 −0.46 (0.07) <0.0001
 A Baseline    
Lactation group 1 0.05 (0.19) 0.80 −0.24 (0.08) 0.00
 2 −0.18 (0.14) 0.20 0.11 (0.09) 0.23
 3+ Baseline    
Vaccine Vaccinated 0.26 (0.15) 0.08 −0.22 (0.07) 0.00
 Control Baseline    
Vaccine × lactation group Vaccinated × 1 −0.54 (0.23) 0.02 NS  
 Vaccinated × 2 −0.43 (0.20) 0.03 NS  
 Vaccinated × 3+ Baseline  NS  
Months since 50/50  0.02 (0.01) 0.01 0.01 (0.01) 0.25
1The unit of analysis in this model is a calendar month. All months during the trial are included in the analysis; 
month since 50/50 vaccination was forced into the model as a covariate. 
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For the analysis of the data, we focused our efficacy 
estimates on cows that received a full vaccination pro-
tocol. Despite the ambition to vaccinate cows according 
to the label vaccination scheme, this was not always 
easy. Inaccurate estimation of duration of pregnancy, 
early loss of pregnancy, abortions, and cows calving 
early were the most important reasons for incomplete 
vaccination. Given that incomplete vaccination due to 
the reasons described here is a reality in many herds, 
it is possible that our estimates of vaccine efficacy are 
overestimated compared with the truly observed vac-
cine efficacy under field conditions.
A novel contribution of the current study was the 
chosen design of the study. By first fully vaccinating 
all cows before calving it was possible to reach a state 
of more or less equal groups of vaccinated and control 
cows. In herds with a year-round calving pattern it may 
be expected that 50% of cows calve at approximately 6 
mo. After reaching 6 mo, vaccination was randomized 
at 50/50. At the time of starting the 50/50 randomiza-
tion, the cohort of unvaccinated cows was later in lac-
tation compared with the vaccinated cows, hence the 
proportion of vaccinated cows will initially increase to 
approximately 65% before falling back to 50%. This in-
crease will be lower when the time to 50/50 is longer, as 
the difference in lactation stage in the fully vaccinated 
and control cohorts will be smaller. These effects can 
be seen in Figure 1. A deviation in ratio of vaccinates 
versus controls above 1 will result in a slight increase in 
power, as the expected number of events will be lower 
in the vaccinated arm of the study (Dohoo, 2004). In 
contrast, when 50/50 vaccination had been started im-
mediately, it would have taken approximately 1.5 yr 
before the 50/50 ratio would have been obtained in the 
full lactating herd.
The chosen study design, with comingling of vacci-
nated and control cows, allowed us to estimate popula-
tion vaccine efficacy within herd using a within-herd 
randomization schedule. The difference between esti-
mates of direct vaccine effects using simple regression 
analysis and population vaccine efficacy using a more 
elaborate mathematical modeling approach was large. 
Simple regression, resulting in an estimate of direct 
vaccine efficacy, showed no significant effects of vac-
Table 5. Modeling the cure parameter (α*) using rate of cure1 
Effect Category
Staphylococcus aureus CNS
Estimate (SE) Pr > |t| Estimate (SE) Pr > |t|
α*  −1.51 (0.09) <0.0001 −0.32 (0.08) 0.00
Herd B 0.92 (0.13) <0.0001 −0.45 (0.07) <0.0001
 A Baseline    
Lactation group 1 0.02 (0.13) 0.85 −0.13 (0.08) 0.11
 2 −0.04 (0.10) 0.67 0.26 (0.09) 0.00
 3+ Baseline    
Vaccine Vaccinated 0.60 (0.12) <0.0001 0.18 (0.07) 0.01
 Control Baseline    
Herd × vaccine B × Vaccinated 0.37 (0.18) 0.04 NS  
 B × Control Baseline    
Months since 50/50  −0.07 (0.01) <0.0001 0.02 (0.01) <0.0001
Months since 50/50 × vaccine Vaccinated 0.11 (0.02) <0.0001 NS  
 Control Baseline    
1The unit of analysis in this model is a calendar month. All months during the trial are included in the analysis; month since 50/50 vaccination 
was forced into the model as a covariate.
Table 6. Estimation of vaccine efficacy with regard to infection transmission, infection cure, and basic 
reproduction ratio 
Parameter Category
Staphylococcus  
aureus CNS
β, transmission Lactation 1 0.25 0.20
 Lactation 2 0.16 0.20
 Lactation 3 −0.30 0.20
α, cure Herd B 0.52  
 Herd A 0.30  
 All 0.41 0.16
R0, basic reproduction ratio Lactation 1 0.56 0.33
 Lactation 2 0.50 0.33
 Lactation 3 0.24 0.33
 All 0.44 0.33
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cination on new infections. Simple regression analysis 
without controlling for exposure environment will 
provide an estimate of direct vaccine efficacy, whereas 
our mathematical modeling resulted in an unbiased es-
timated of overall population vaccine efficacy (Halloran 
et al., 1997). The estimate of direct vaccine efficacy in 
comingled populations is expected to be biased toward 
no effect (Halloran et al., 1998, 2008). Therefore, as 
expected, the estimates of population vaccine efficacy 
were larger than the direct effect estimates. These pop-
ulation vaccine efficacy estimates were likely unbiased 
when proper control for total exposure experience was 
included. Related to the significant overall population 
efficacy of vaccination was the finding that the inclusion 
of total exposure experience in modeling of new infec-
tions was highly significant for both Staph. aureus and 
CNS. The very same finding was reported for Staph. 
aureus previously by Lam et al. (1996) and Barlow et 
al. (2013). Modeling infection transmission of CNS was 
reported by Reksen et al. (2012). In the current study, 
inclusion of total exposure experience was significant on 
1 farm, but not important on a second farm. Although 
CNS exposure experience was important in both farms 
in the current study, large differences existed between 
farms with regard to CNS infection dynamics. This 
difference between farms may be explained by the 
dominant CNS species that is present in each particular 
farm. Until now, CNS species were not determined on 
the isolates collected in the current study. Future work 
on the collected isolates may provide more insight.
Previous studies on staphylococcal vaccination in 
dairy cows, as reviewed by Middleton et al. (2009) and 
Pereira et al. (2011), have shown relatively low vaccine 
efficacy or no vaccine efficacy at all. However, all the 
reviewed studies only reported direct vaccine efficacy 
and did not attempt to estimate overall population es-
timates. As staphylococcal IMI are mostly subclinical, 
and reducing infection transmission is the key outcome 
of interest, we would argue that carefully designed field 
studies with appropriate population dynamics-based 
vaccine efficacy estimates are essential to allow unbi-
ased vaccine efficacy estimates. The design and analy-
ses that we report here may therefore be of interest 
for future studies on staphylococcal vaccine efficacy in 
dairy herds (Daum and Spellberg, 2012).
In the analysis of new infection risk with Staph. 
aureus, a significant interaction of month in lactation 
with vaccination group was observed, with an increased 
risk with increasing months in lactation. Similarly, risk 
of infection increased with lactation number. Vaccine 
effects were observed throughout all analyses that 
were performed. In the analyses that we performed, we 
observed a significant decrease in prevalence of Staph. 
aureus in vaccinated cows compared with control cows, 
particularly later in lactation (Figure 2a). Rate of new 
infection and prevalence of CNS tended to be lower in 
vaccinated cows compared with control cows (Figures 
2b and 3b). Duration of infection was significantly 
shorter in vaccinated cows compared with control cows 
for both Staph. aureus and CNS (Figure 4a and b). The 
observed reduction in duration will benefit the affected 
cows but will also reduce the overall herd exposure 
experience of the other cows in the herd, resulting in 
an important contribution to indirect vaccine efficacy 
(Halloran et al., 1997, 1998).
Diagnosing IMI is not straightforward. Classical 
culture of milk samples has a limited sensitivity, there-
fore diagnostic errors will occur. In the current study 
we used monthly samples of all quarters of all cows, 
resulting in an overall increased sensitivity to detect 
IMI. However, the precise duration of the IMI may be 
underestimated. Similarly, we defined cure- or culture-
negative based on 2 subsequent samples, with the ex-
ception of the edges of the study (start and end) where 
single samples were sufficient to determine the absence 
of infection. We chose the latter definition to increase 
sensitivity in the diagnosis of cure, but obviously at 
the cost of reduced specificity. These diagnostic errors 
occur with equal probability in vaccinates and controls 
and are therefore not likely to bias the results of the 
study. Other simulation studies have shown that impre-
cise diagnosis of IMI in comparative studies generally 
results in a bias toward the null hypothesis of no effect 
(Morant et al., 1988).
Modeling infection dynamics showed a significantly 
lower transmission parameter and rate of cure parame-
ter for CNS across farms and groups of cows. For Staph. 
aureus, a lower transmission parameter was present in 
first lactation animals, and this effect of vaccination 
decreased with increasing lactation number. It has been 
shown before that IMI with Staph. aureus in older cows 
are less easily influenced by interventions (Barkema et 
al., 2006), most likely due to chronicity of the infection.
The farms showed a large difference in their ability 
to control infection during the study. For both farms, 
the prevalence of CNS remained more or less constant, 
but this was due to a slight increase in the control 
group and a decrease in prevalence in the vaccination 
group. Prevalence of Staph. aureus remained the same 
or slightly increased in farm A but dropped dramati-
cally to a very low prevalence in farm B. Farm B was 
also actively culling Staph. aureus cows at a higher rate 
compared with non-Staph. aureus cows (P > 0.05). The 
farm managers had no knowledge of the culture data 
during the trial, so the increase culling of Staph. au-
reus cows was based on the actual performance of the 
animals and not because of an increased culling policy 
for known Staph. aureus cows. Culling policy in farm 
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B was mostly based on fertility, lameness, and milk 
production.
The observed vaccine efficacy may vary depending 
on farm-specific characteristics, such as strain types 
(Smith et al., 1998; Barlow et al., 2013) and farm man-
agement practices (Lam et al., 1997), as we identified 
significant differences between farms. The known farm 
management practices associated with infection dynam-
ics of Staph. aureus included treatment protocols, seg-
regation and culling of known infected animals, milking 
procedures, and milking equipment (Barkema et al., 
2006; Olde Riekerink et al., 2010). These differences in 
farm management practices will likely also be involved 
in determining the observed efficacy of staphylococcal 
vaccinations on dairy farms. For example, on farms 
with good management practices, R0 for Staph. aureus 
would be reduced from 1.5 to 0.83, whereas vaccination 
on farms with poor management would reduce R0 from 
5 to 2.75. In the latter example, Staph. aureus would 
show a reduced prevalence but remain endemic despite 
vaccination, whereas, in the first example, Staph. au-
reus would eventually be eliminated due to vaccination. 
In the present study we did not perform a cost-benefit 
analysis of the vaccine regimen used in this field study. 
Eventually, such a cost-benefit analysis will be essential 
to decide under what infection conditions vaccination 
would be economically beneficial to the farm.
CONCLUSIONS
Vaccine efficacy was moderate in our field trial in 2 
commercial dairy herds. Vaccination was able to re-
duce the basic reproduction ratio of CNS and Staph. 
aureus in both herds. The data indicated that vaccina-
tion will result in reduction of the basic reproduction 
ratio of Staph. aureus by approximately 45% and the 
basic reproduction ratio for CNS by approximately 
35%. Efficacy was dependent upon the age group of 
the animals, particularly for Staph. aureus, where first 
lactation animals showed a significantly higher value 
compared with animals in third and higher lactation. 
The observed vaccine efficacy may vary depending on 
farm management practices, as we identified significant 
differences between farms. Vaccination is a valuable 
tool in reducing incidence and prevalence of staphylo-
coccal infection in herds. Vaccine utilization will need 
to be combined with excellent milking procedures, cull-
ing of known infected cattle, and other management 
procedures to effectively reduce incidence and duration 
of infection.
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